Skip to main content
Top
Published in: Annals of Hematology 1/2004

01-01-2004 | Original Article

Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency

Authors: M. de Montalembert, G. Lenoir

Published in: Annals of Hematology | Issue 1/2004

Login to get access

Abstract

Asplenic and hyposplenic patients have an increased risk for overwhelming pneumococcal infections, even several decades after splenectomy. Pneumococcal vaccination and daily oral administration of penicillin V are recommended to prevent such infections, 2–5 years after splenectomy, and for at least 5 years in children affected with sickle cell disease. In order to assess whether the infectious risk is actually known and prevented, we interviewed physicians (belonging to a general practitioner and pediatrician network) who followed patients having undergone a splenectomy and/or children with sickle cell disease under 5 years of age. We received replies from 104 physicians monitoring 152 patients replied. Potential infection risk was not known for 28% of the asplenic patients and 40% of the children with sickle cell disease. Only 75% of the asplenic patients and 36% of the children with sickle cell disease had been vaccinated against pneumococcus. Of the patients who had undergone splenectomy, 27% had been treated with an antibiotic after surgery and 60% had discontinued it, the vast majority of them during the same year. Of the children with sickle cell disease, 48% were not receiving an antibiotic. This study demonstrates that risk of infections in asplenic patients is widely misunderstood, indicating the urgent need to improve their management.
Literature
1.
go back to reference Sumaraju V, Smith LG, Smith SM (2001) Infectious complications in asplenic hosts. Infect Dis Clin North Am 15:551–565PubMed Sumaraju V, Smith LG, Smith SM (2001) Infectious complications in asplenic hosts. Infect Dis Clin North Am 15:551–565PubMed
2.
go back to reference Hermine O (1997) Splenectomy. In: Varet (ed) Le livre de l’interne. Médecine-Sciences Flammarion, Paris, pp 289–294 Hermine O (1997) Splenectomy. In: Varet (ed) Le livre de l’interne. Médecine-Sciences Flammarion, Paris, pp 289–294
3.
go back to reference Holdsworth RJ, Irving AD, Cuschieri A (1991) Postsplenectomy sepsis and mortality rate: actual versus perceived risk. Br J Surg 78:1031–1038PubMed Holdsworth RJ, Irving AD, Cuschieri A (1991) Postsplenectomy sepsis and mortality rate: actual versus perceived risk. Br J Surg 78:1031–1038PubMed
4.
go back to reference Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E, for the Cooperative Study Group of Sickle Cell Disease (1995) Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 86:776–783PubMed Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E, for the Cooperative Study Group of Sickle Cell Disease (1995) Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 86:776–783PubMed
5.
go back to reference Thomas C, Lemerle S, Bernaudin F, Feingold J, Guilloud-Bataille M, Reinert P (1996) Drépanocytose: étude de la mortalité pédiatrique en Ile de France de 1985 à 1992. Arch Pediatr 3:445–451 Thomas C, Lemerle S, Bernaudin F, Feingold J, Guilloud-Bataille M, Reinert P (1996) Drépanocytose: étude de la mortalité pédiatrique en Ile de France de 1985 à 1992. Arch Pediatr 3:445–451
6.
go back to reference Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, Diamond S, Holbrook T, Gill FM, Ritchey K, Falletta JM for the Prophylactic Penicillin Study Group (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 314:1593–1599PubMed Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, Diamond S, Holbrook T, Gill FM, Ritchey K, Falletta JM for the Prophylactic Penicillin Study Group (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 314:1593–1599PubMed
7.
go back to reference Comité des maladies infectieuses et d’immunisation. Société canadienne de pédiatrie (1999) La prévention et le traitement des infections bactériennes chez les enfants aspléniques ou hypospléniques. Paediatr Child Health 4:427–431 Comité des maladies infectieuses et d’immunisation. Société canadienne de pédiatrie (1999) La prévention et le traitement des infections bactériennes chez les enfants aspléniques ou hypospléniques. Paediatr Child Health 4:427–431
8.
go back to reference Schilling RF(1995) Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 122:187–188PubMed Schilling RF(1995) Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 122:187–188PubMed
9.
go back to reference Pass KA, Harris K, Lorey F, Choi R, Kling MA (2000) Update: newborn screening for sickle cell disease—California, Illinois, and New York, 1998. MMWR Morb Mortal Wkly Rep 49:729–731PubMed Pass KA, Harris K, Lorey F, Choi R, Kling MA (2000) Update: newborn screening for sickle cell disease—California, Illinois, and New York, 1998. MMWR Morb Mortal Wkly Rep 49:729–731PubMed
Metadata
Title
Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency
Authors
M. de Montalembert
G. Lenoir
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 1/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0779-x

Other articles of this Issue 1/2004

Annals of Hematology 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.